Tirofiban (Aggrastat®) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model

Thoracic and Cardiovascular Surgeon

Volumn 54, Issue 3, 2006, Pages 162-167

  Straub, A ^a,b   Azevedo, R ^a   Beierlein, W ^a   Wendel, H P ^a   Dietz, K ^a   Ziemer, G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Extracorporeal circulation; GP IIb IIIa inhibition; Inflammation; Platelets

Indexed keywords

ADENOSINE; ADENOSINE DIPHOSPHATE; APROTININ; CD15 ANTIGEN; COROTROP; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; MILRINONE; PADGEM PROTEIN; PHOSPHODIESTERASE INHIBITOR; PROTEIN INHIBITOR; THROMBIN RECEPTOR; TIROFIBAN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; PEPTIDE; SERINE PROTEINASE INHIBITOR; TYROSINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; DRUG INHIBITION; EXTRACORPOREAL CIRCULATION; FLOW CYTOMETRY; GRANULOCYTE; HEART SURGERY; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; BINDING COMPETITION; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

APROTININ; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; BLOOD PLATELETS; DIPYRIDAMOLE; EXTRACORPOREAL CIRCULATION; FLOW CYTOMETRY; GRANULOCYTES; HUMANS; MALE; MILRINONE; P-SELECTIN; PEPTIDES; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SERINE PROTEINASE INHIBITORS; TYROSINE;

EID: 33646448553     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872952     Document Type: Article

References (27)

1. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-1205
2. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-2152
3. Doré M. Platelet-leukocyte interactions. Am Heart J 1998; 135 (5 Pt 2 Suppl): S146-151
4. Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood 1994; 83: 2498-2507
5. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-231
6. Bizzarri F, Scolletta S, Tucci E et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-1185
7. Dyke CM, Bhatia D, Lorenz TJ et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy. Ann Thorac Surg 2000; 70: 866-871; discussion 871-872
8. Genoni M, Zeller D, Bertel O, Maloigne M, Turina M. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. J Thorac Cardiovasc Surg 2001; 122: 630-632
9. Straub A, Wendel HP, Azevedo R, Ziemer G. The GP IIb/IIIa inhibitor abciximab (ReoPro®) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005; 27: 617-621
10. Koster A, Chew DP, Kuebler W et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-347
11. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80
12. Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther 2003; 25: 2564-2574
13. Schneider DJ, Herrmann HC, Lakkis N et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91: 334-336
14. Anfossi G, Massucco P, Piretto V et al. Interplay between milrinone and adenosine in the inhibition of human platelet response. Gen Pharmacol 1996; 27: 1149-1154
15. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the anti-platelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-18
16. Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg 2001; 92: 830-836
17. Wendel HP, Hauser N, Briquet F, Ziemer G. Hemocompatibility of medical connectors with biopassive or bioactive surface coatings. J Biomater Appl 2002; 17: 5-17
18. Straub A, Azevedo R, Beierlein W, Wendel H, Dietz K, Ziemer G. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermie circulatory arrest. Thromb Haemost 2005; 94: 115-122
19. Kondo N, Wakayama F, Suzuki Y, Fukui K, Takaya S, Fukuda I. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor. Thromb Res 2004; 113: 303-310
20. Hiramatsu Y, Gikakis N, Anderson HL 3 rd et al. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-193
21. Suzuki Y, Hillyer P, Miyamoto S et al. Integrilin prevents prolonged bleeding times after cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 373-381
22. Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002; 73: 325-330
23. Schmid C, Wilhelm M, Rothenburger M et al. Effect of high dose platelet inhibitor treatment on thromboembolism in Novacor patients. Eur J Cardiothorac Surg 2000; 17: 331-335
24. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin Ann Thorac Surg 2001; 72: S1808-1813
25. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 355-366
26. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-756
27. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002; 13: 401-406